Initiated Equal Weight X

MNK Mallinckrodt plc

Barclays

Downgrades Overweight Neutral X

MNK Mallinckrodt plc

Piper Jaffray

Downgrades Buy Hold X

MNK Mallinckrodt plc

Jefferies

Initiated Hold X

MNK Mallinckrodt plc

SunTrust

Upgrades Hold Buy X

MNK Mallinckrodt plc

Canaccord Genuity

$34 $40

Downgrades Neutral Sell X

MNK Mallinckrodt plc

Goldman

Reiterated Neutral X

MNK Mallinckrodt plc

B. Riley FBR

$20 $37

Downgrades Outperform Mkt Perform X

MNK Mallinckrodt plc

Raymond James

Reiterated Hold X

MNK Mallinckrodt plc

Stifel

$18 $30

Initiated Neutral X

MNK Mallinckrodt plc

B. Riley FBR, Inc.

$15

Reiterated Neutral X

MNK Mallinckrodt plc

Mizuho

$21 $16

Downgrades Eq Weight Underweight X

MNK Mallinckrodt plc

Barclays

$23 $20

MNK  Mallinckrodt plc

Mallinckrodt public limited company develops, manufactures, markets and distributes branded and generic specialty pharmaceutical products and therapies. The Company focuses on various therapeutic areas, such as autoimmune and rare disease specialty areas, including neurology, rheumatology, nephrology, ophthalmology and pulmonology; immunotherapy and neonatal critical care respiratory therapies; analgesics and hemostasis products, and central nervous system drugs. Its segments include Specialty Brands and Specialty Generics. The Specialty Brands segment produces and markets branded pharmaceutical products and therapies. The Specialty Generics segment produces and markets specialty generic pharmaceuticals and active pharmaceutical ingredient (API) consisting of biologics, medicinal opioids, synthetic controlled substances, acetaminophen and other active ingredients. Its product portfolio includes Acthar, Inomax, Ofirmev, Therakos immunotherapy, Hemostasis products and StrataGraft.